Sie sind hier: UHH > Chemie > Institute und Abteilungen > Biochemie und Molekularbiologie > Publikationen > Peter Heisig
Inhalt:
2011 | |
| 1 |
Commonality among Fluoroquinolone-Resistant Sequence Type ST131 Extraintestinal Escherichia coli Isolates from Humans and Companion Animals in Australia Joanne L. Platell; Rowland N. Cobbold; James R. Johnson; Anke Heisig; Peter Heisig; Connie Clabots; Michael A. Kuskowski; Darren J. Trott Antimicrobial Agents and Chemotherapy 55, 3782-3787 (2011) |
| 2 |
Identification of variables for aerobic bacterial density al clinical relevant skin sites Mirja Reichel; Peter Heisig; Günter Kampf Journal of Hospital Infection 78, 5-10 (2011) |
| 3 |
CMY-42, a Novel Plasmid-Mediated CMY-2 Variant AmpC β-Lactamase Moritz Hentschke; Stathis D. Kotsakis; Manuel Wolters; Peter Heisig; Vivi Miriagou; Martin Aepfelbacher Microbial Drug Resistance 17, 165-169 (2011) |
2010 | |
| 4 |
Skin bacteria after chlorhexidine exposure-is there a difference in response to human β-Defensin-3? Mirja Reichel; Anke Heisig; Peter Heisig; Günter Kampf European Journal of Clinical Microbiology & Infectious Diseases 29, 623-632 (2010) |
| 5 |
Antibacterial activity of finafloxacin under different pH conditions against isogenic strains of Escherichia coli expressing combinations of defined mechanisms of fluoroquinolone resistance Nadine-C. Emrich; Anke Heisig; Will Stubbings; Harald Labischinski; Peter Heisig Journal of Antimicrobial Chemotherapy 65, 2530-2533 (2010) |
| 6 |
Harnwegsinfektionen und Antibiotikaresistenz (Urinary tract infections and antibiotic resistance) Peter Heisig Urologe A. 49, 612-617 (2010) |
| 7 |
Identification of Qnr and aac(6')-1b-cr plasmid-mediated fluoroquinolone resistance determinants in multidrug-resistant Enterobacter spp. isolated from extraintestinal infections in companion animals Justine S. Gibson; Rowland N. Cobbold; Peter Heisig; Hanna E. Sidjabat; Myat T. Kyaw-Tanner; Darren J. Trott Veterinary Microbiology 143, 329-336 (2010) |
| 8 |
Fluoroquinolone resistance mechanisms in multidrug-resistant Escherichia coli isolated from extraintestinal infections in dogs Justine S. Gibson; Rowland N. Cobbold; Myat T. Kyaw-Tanner; Peter Heisig; Darren J. Trott Veterinary Microbiology 146, 161-166 (2010) |
2009 | |
| 9 |
Alcohols for skin antisepsis at clinically relevant skin sites Mirja Reichel; Peter Heisig; Thomas Kohlmann; Günter Kampf Antimicrobial Agents and Chemotherapy 53, 4778-4782 (2009) |
| 10 |
The role of intra- and extragenic compensatory mutations in the suppression of fluoroquinolone resistance in a Salmonella Typhimurium gyrA mutant (D87G) Antje Preisler; Peter Heisig Journal of Antimicrobial Chemotherapy 63, 290-294 (2009) |
| 11 |
Type II topoisomerases-inhibitors, repair mechanisms and mutations Peter Heisig Mutagenesis 24, 465-469 (2009) |
2008 | |
| 12 |
Pitfalls in efficacy testing - how important is the validation of neutralization of chlorhexidine digluconate? Mirja Reichel; Peter Heisig; Günter Kampf Annals of Clinical Microbiology and Antimicrobials 7, 20 (2008) |
| 13 |
Molecular characterization of linezolid resistance in two vancomycin-resistant (VanB) Enterococcus faecium isolates using Pyrosequencing Björn Saager; Holger Rohde; Björn S. Timmerbeil; G. Franke; Werner Pothmann; J. Dahlke; Stefanie Scherpe; Ingo Sobottka; Peter Heisig; M. A. Horstkotte European Journal of Clinical Microbiology & Infectious Diseases 27, 873-878 (2008) |
| 14 |
Emergence of Linezolid Resistance in a Methicillin Resistant Staphylococcus aureus Strain Moritz Hentschke; Björn Saager; M. A. Horstkotte; Stefanie Scherpe; Manuel Wolters; H. Kabisch; R. Grosse; Peter Heisig; Martin Aepfelbacher; Holger Rohde Infection 36, 85-87 (2008) |
| 15 |
Role of global regulator rma for multidrug efflux-mediated fluoroquinolone resistance in Salmonella Silke Feuerriegel; Peter Heisig Microbial Drug Resistance 14, 259-263 (2008) |
| 16 |
Bacterial Resistance to Antibiotics Peter Heisig Encyclopedia of Molecular Pharmacology 102-106 (2008) |
| 17 |
Characterization of the Quinolone-Gyrase-Interaction Using Docking, Molecular-Dynamics and Site-Directed Mutagenesis Jörn Lenz; Thomas Lemcke; Peter Heisig; Andrew E. Torda -/- Herausgeber: Ulrich H. E. Hansmann; Jan H. Meinke; Sandipan Mohanty; Walter Nadler; Olav Zimmermann From Computational Biophysics to Systems Biology (CBSB08). Proceedings of the NIC Workshop 2008 40, 289-292 (2008), Verlag: John von Neumann Institute for Computing, Jülich |
2007 | |
| 18 |
Nachweis eines Carbapenem-resistenten Klebsiella-Pneumoniae-Isolats in Norddeutschland Björn S. Timmerbeil; Björn Saager; Stefanie Scherpe; Enno Stürenburg; Peter Heisig Chemotherapie Journal 16, 186-188 (2007) |
| 19 |
Nachweis der antibakteriellen Aktiviät von Chitosan Peter Heisig; Tatjana Claußen; Gerd Mayer GMS Krankenhaushygiene Interdisziplinär 2 (2) 1-7 (2007) |
2006 | |
| 20 |
Role of novel gyrA mutations in the suppression of the fluoroquinolone resistance genotype of vaccine strain Salmonella typhimurium vacT (gyrA D87G) Antje Preisler; Mobarak Abu Mraheil; Peter Heisig Journal of Antimicrobial Chemotherapy 57, 430-436 (2006) |
| 21 |
Effects of different drying processes on the material properties of bacterial cellulose membranes Christian Clasen; Bano M. Sultanova; Tim Axel Wilhelms; Peter Heisig; Werner-Michael Kulicke Macromolecular Symposia 244 (New Cellulose Products and Composites) 48-58 (2006) |
| 22 |
Wirkungs- und Resistenzmechanismen der β-Lactam-Antibiotika: Penicillin-bindende Proteine, ß-Lactamasen und Signalproteine (Penicillin binding proteins, β-lactamases and signal proteins. Mechanisms of action and resistance of β-lactam antibiotics) Peter Heisig Pharmazie in Unserer Zeit 35, 400-408 (2006) |
| 23 |
Antibakterielle Aktivität der Chitosan-haltigen Wundauflage Chitoskin in vitro (Antibacterial Activity In Vitro of Chitoskin - a Chitosan-Containing Wound Dressing) Tatjana Claußen; Gerd Mayer; Peter Heisig Zeitschrift für Wundauflage 6, 304-308 (2006) |
2005 | |
| 24 |
Hase und Igel: Wettlauf mit resistenten Bakterien (Rabbit and hedgehog: Race with resistant bacteria) Ulrike Holzgrabe; Peter Heisig Pharmazeutische Zeitung 150, 2204-2213 (2005) |
2004 | |
| 25 |
A mutation in Escherichia coli DNA gyrase conferring quinolone resistance results in sensitivity to drugs targeting eukaryotic topoisomerase II Thomas Grüger; John L. Nitiss; Anthony Maxwell; E. Lynn Zechiedrich; Peter Heisig; Siegfried Seeber; Yves Pommier; Dirk Strumberg Antimicrobial Agents and Chemotherapy 48, 4495-4504 (2004) |
| 26 |
Wirkungs- und Resistenzmechanismen: Was ist neu an Ketoliden und Oxazolidinonen? (What's new in ketolides and oxazolidinones? Reactions and resistance mechanisms) Peter Heisig Pharmazie in Unserer Zeit 33, 10-19 (2004) |
2003 | |
| 27 |
Synthesis and antimicrobial activity of tetrodecamycin partial structures Franz F. Paintner; Lars Allmendinger; Gerd Bauschke; Caroline Berns; Peter Heisig Bioorganic & Medicinal Chemistry 11, 2823-2833 (2003) |
| 28 |
Clinically significant borderline resistance of sequential clinical isolates of Klebsiella pneumoniae Florian Wagenlehner; Peter Heisig; Christine Irtenkauf; Frank Notka; Jochen Decker; Norbert Lehn; Hans-Jörg Linde International Journal of Antimicrobial Agents 22, 367-373 (2003) |
| 29 |
Topoisomerase IV mutations in quinolone-resistant Salmonellae selected in vitro Heike Hansen; Peter Heisig Microbial Drug Resistance 9, 25-32 (2003) |
2002 | |
| 30 |
Fluorchinolone: Mechanismen der Resistenzentwicklung Norbert Lehn; Hans-Jörg Linde; Peter Heisig Chemotherapie Journal 11 (Suppl. 20) 15-17 (2002) |
| 31 |
Increase in MICs of ciprofloxacin in vivo in two closely related clinical isolates of enterobacter cloacae Hans-Jörg Linde; Frank Notka; Christine Irtenkauf; Jochen Decker; Jens Wild; Hans-Helmut Niller; Peter Heisig; Norbert Lehn Journal of Antimicrobial Chemotherapy 49, 625-630 (2002) |
| 32 |
Der bakteriellen Antibiotikaresistenz auf der Spur Peter Heisig Medizinische Monatsschrift für Pharmazeuten 25 (1) 1-2 (2002) |
2001 | |
| 33 |
In vitro development of resistance to six quinolones in Streptococcus pneumoniae, Streptococcus pyogenes, and Staphylococcus aureus Mechthild Boos; Susanne Mayer; Ansgar Fischer; Karl Köhrer; Sibylle Scheuring; Peter Heisig; Jan Verhoef; Ad C. Fluit; Franz-Josef Schmitz Antimicrobial Agents and Chemotherapy 45, 938-942 (2001) |
| 34 |
Resistance to moxifloxacin in toxigenic Clostridium difficile isolates is associated with mutations in gyrA Grit Ackermann; Yajarayma J. Tang; Robert Kueper; Peter Heisig; Arne C. Rodloff; Joseph Silva; Stuart H. Cohen Antimicrobial Agents and Chemotherapy 45, 2348-2353 (2001) |
| 35 |
In vitro activities of fluoroquinolones against the spirochete Borrelia burgdorferi Peter Kraiczy; Judith Weigand; Thomas A. Wichelhaus; Peter Heisig; Herbert Backes; Volker Schäfer; Georg Acker; Volker Brade; Klaus-Peter Hunfeld Antimicrobial Agents and Chemotherapy 45, 2486-2494 (2001) |
| 36 |
In vitro activity of sitafloxacin against Clostridium difficile Grit Ackermann; Yajarayma J. Tang; Arne C. Rodloff; Joseph Silva; Stuart H. Cohen; Peter Heisig Journal of Antimicrobial Chemotherapy 47, 722-724 (2001) |
| 37 |
Effect of Gemifloxacin to in vitro Selected Mutants and Field Isolates of Salmonella ssp. with Mutations in gyrA, gyrB, parC and marR Heike Hansen; Wolfgang Rabsch; Peter Heisig Journal of Antimicrobial Chemotherapy 47 (Suppl. 1) 37-37 (2001) |
| 38 |
Topoisomerases Peter Heisig Medizinische Forschung 12, 59-66 (2001) |
| 39 |
Wirkungs- und Resistenzmechanismen der Chinolone: Actio und Reactio (Action and reaction: properties and resistance mechanisms of quinolones) Peter Heisig; Bernd Wiedemann Pharmazie in Unserer Zeit 30, 382-393 (2001) |
| 40 |
Inhibitors of bacterial topoisomerases: mechanisms of action and resistance and clinical aspects Peter Heisig Planta Medica 67, 3-12 (2001) |
| 41 |
Topoisomerasen Peter Heisig -/- Herausgeber: Ernst Mutschler; Hartmut Lode; Bernd Wiedemann Medizinische Forschung 12 (Bakterielle und virale Resistenz: Epidemiologie, Mechanismen, klinische Relevanz und therapeutische Konsequenzen) 59-66 (2001), Verlag: Akademie der Wissenschaften und Literatur, Mainz; Schwabe & Co. AG Verlag, Basel |
2000 | |
| 42 |
Prevalence of gyrA, gyrB, parC, and parE mutations in clinical isolates of Streptococcus pneumoniae with decreased susceptibilities to different fluoroquinolones and originating from worldwide surveillance studies during the 1997-1998 respiratory season Mark E. Jones; Daniel F. Sahm; Nele Martin; Sibylle Scheuring; Peter Heisig; Clyde Thornsberry; Karl Köhrer; Franz-Josef Schmitz Antimicrobial Agents and Chemotherapy 44, 462-466 (2000) |
| 43 |
In vivo increase in resistance to ciprofloxacin in Escherichia coli associated with deletion of the C-terminal part of MarR Hans-Jörg Linde; Frank Notka; Michaela Metz; Bernd Kochanowski; Peter Heisig; Norbert Lehn Antimicrobial Agents and Chemotherapy 44, 1865-1868 (2000) |
| 44 |
Chinolonresistenzmechanismen bei grampositiven Kokken Susanne Mayer; Peter Heisig; Franz-Josef Schmitz Der Mikrobiologe 10, 13-16 (2000) |
| 45 |
In vitro activity of gemifloxacin and five other fluoroquinolones against defined isogenic mutants of Escherichia coli, Pseudomonas aeruginosa and Staphylococcus aureus Ansgar Schulte; Peter Heisig Journal of Antimicrobial Chemotherapy 46, 1037-1038 (2000) |
| 46 |
β-Lactamase expression in Yersinia enterocolitica biovars 1A, 1B and 3 Ingo Stock; Peter Heisig; Bernd Wiedemann Journal of Medical Microbiology 49, 403-408 (2000) |
| 47 |
"Medizinische Mikrobiologie für Pharmazeuten" oder Pharmazeutische Microbiologie ("Medical microbiology for pharmacists" or pharmaceutical microbiology) Peter Heisig; Bernd Wiedemann Medizinische Monatsschrift für Pharmazeuten 23, 173-175 (2000) |
| 48 |
Chinolonantibiotika - Wirkungsweise und Resistenzmechanismen (Chinolone antibiotics. Mode of action and resistance mechanisms) Susanne Mayer; Franz-Josef Schmitz; Peter Heisig MTA 15, 77-80 (2000) |
| 49 |
PCR in der medizinischen und pharmazeutischen Analytik Peter Heisig -/- Herausgeber: Oliver Kayser; Rainer H. Müller Pharmazeutische Biotechnologie 225-238 (2000), Verlag: Wissenschaftliche Verlagsgesellschaft, Stuttgart |
| 50 |
Classification of bacteria using sequences of gyr and par genes Peter Heisig; Yolanda Fuchs-Gomez Patent: WO 2000061796 (A1) 2000-10-19 |
1999 | |
| 51 |
Comparative activities of clinafloxacin, grepafloxacin, levofloxacin, moxifloxacin, ofloxacin, sparfloxacin, and trovafloxacin and nonquinolones linezolid, quinupristin-dalfopristin, gentamicin, and vancomycin against clinical isolates of ciprofloxacin-resistant and -susceptible Staphylococcus aureus strains Mark E. Jones; Maarten R. Visser; Miriam Klootwijk; Peter Heisig; Jan Verhoef; Franz-Josef Schmitz Antimicrobial Agents and Chemotherapy 43, 421-423 (1999) |
| 52 |
Impact of gyrA and parC mutations on quinolone resistance, doubling time, and supercoiling degree of Escherichia coli Simone Bagel; Volker Hüllen; Bernd Wiedemann; Peter Heisig Antimicrobial Agents and Chemotherapy 43, 868-875 (1999) |
| 53 |
Association of alterations in ParC and GyrA proteins with resistance of clinical isolates of Enterococcus faecium to nine different fluoroquinolones Sylvain Brisse; Ad C. Fluit; Ulrich Wagner; Peter Heisig; Dana Milatovic; Jan Verhoef; Sibylle Scheuring; Karl Köhrer; Franz-Josef Schmitz Antimicrobial Agents and Chemotherapy 43, 2513-2516 (1999) |
| 54 |
Bakterielle Resistenz gegenüber Chinolonen (Bacterial resistance to quinolones (ciprofloxacin)) Bernd Wiedemann; Peter Heisig Chemotherapie Journal 8, 99-107 (1999) |
| 55 |
The effect of moxifloxacin on its target topoisomerases from Escherichia coli and Staphylococcus aureus Holger Schedletzky; Bernd Wiedemann; Peter Heisig Journal of Antimicrobial Chemotherapy 43 (Suppl. B) 31-37 (1999) |
| 56 |
Expression of β-lactamases in Yersinia enterocolitica strains of biovars 2, 4, and 5 Ingo Stock; Peter Heisig; Bernd Wiedemann Journal of Medical Microbiology 48, 1023-1027 (1999) |
| 57 |
Neue 4-Chinolonderivate im Überblick (New 4-quinolone derivatives. An overview) Ulrike Holzgrabe; Peter Heisig Pharmazie in Unserer Zeit 28, 30-35 (1999) Erratum: Pharmazie in Unserer Zeit 28, 285-285 (1999) |
| 58 |
DNA als Arzneistoff (Application of DNA as drug) Peter Heisig Pharmazie in Unserer Zeit 28, 130-137 (1999) |
| 59 |
Mechanisms of antibiotic resistance in Gram-negative bacteria of clinical importance Peter Heisig Nova Acta Leopoldina 78 (307, Problems of Relevant Infectious Diseases) 257-267 (1999) |
1997 | |
| 60 |
Fluorchinoloncarbonsäuren - moderne antibakterielle Chemotherapeutika mit breitem Wirkungsspektrum Peter Heisig Arzneimitteltherapie 15, 14-23 (1997) |
| 61 |
Mechanisms and epidemiology of fluoroquinolone resistance in Enterobacteriaceae Peter Heisig BIOspektrum Sonderband (Antibiotic resistance: recent developments and future perspectives : mechanisms and spread : new targets for antimicrobial agents) 42-46 (1997) |
| 62 |
GyrA Mutationen bei fluorchinolonresistenten Enterobakterien L. Y. Fuchs; C. Diaz; Barbara Kratz; Peter Heisig Chemotherapie Journal 6, 56-57 (1997) |
| 63 |
Antibacterial activity of grepafloxacin Bernd Wiedemann; Peter Heisig Journal of Antimicrobial Chemotherapy 40 (Suppl. A) 19-25 (1997) |
| 64 |
Molekulare Genetik Rolf Knippers, 7. Durchgesehene und korrigierte Auflage 1997, Georg Thieme Verlag, Stuttgart, 508 S., 476 farb. Abb., 76 Tab., kart. DM 84,-, ISBN 3-13-47707-5 Peter Heisig Pharmazie in Unserer Zeit 26, 322-323 (1997) |
| 65 |
Simon, C., Stille, W.: Antibiotika-Therapie in Klinik und Praxis, 9. Auflage 1997, Verlag Schattauer, Stuttgart, New York, 672 S., 57 Abb., 93 Tab., DM 78,-, ISBN 3-7945-1755-5 Peter Heisig Pharmazie in Unserer Zeit 26, 323-323 (1997) |
| 66 |
Verbreitung und Mechanismen der Resistenz gegenüber Fluorchinolonen Peter Heisig; Norbert Lehn Symposium MEDICAL 8 (3) 16-17 (1997) |
| 67 |
Mechanismen und Epidemiologie hoher Fluorchinolonresistenz bei Escherichia coli und anderen Gram-negativen Bakterien Peter Heisig Habilitationsschrift, Bonn (1997) |
1996 | |
| 68 |
Genetic evidence for a role of parC mutations in development of high-level fluoroquinolone resistance in Escherichia coli Peter Heisig Antimicrobial Agents and Chemotherapy 40, 879-885 (1996) |
| 69 |
Synthesis and biological activities of new N1-aryl substituted quinolone antibacterials Jens Jürgens; Holger Schedletzky; Peter Heisig; Joachim K. Seydel; Bernd Wiedemann; Ulrike Holzgrabe Archiv der Pharmazie 329, 179-190 (1996) |
| 70 |
Klinische Fluorchinolonresistenz bei E.coli (Chemical fluoroquinolone resistance of Escherichia coli: importance of gyrA-mutation on the serine-83 codon) Peter Heisig; Daniela Olsoczki; Norbert Lehn; Bernd Wiedemann Chemotherapie Journal 5, 185-188 (1996) |
1995 | |
| 71 |
Identification of DNA Gyrase A mutations in ciprofloxacin resistant isolates of Salmonella typhimurium from men and cattle in Germany Peter Heisig; Barbara Kratz; Elke Halle; Yvonne Gräser; Martin Altwegg; Wolfgang Rabsch; Jakob-Peter Faber Microbial Drug Resistance 1, 211-218 (1995) |
| 72 |
Gene Expression - General and Cell Type Specific Von Michael Karin (Hrsg.), Birkhäuser Verlag Basel 1993, DM 188,-, ISBN 3-7643-3605-6 Peter Heisig Pharmazie in Unserer Zeit 24, 297-297 (1995) |
1994 | |
| 73 |
Characterization of fluoroquinolone-resistant mutants of Escherichia coli selected in vitro Peter Heisig; Regina Tschorny Antimicrobial Agents and Chemotherapy 38, 1284-1291 (1994) |
| 74 |
Mechanismen bakterieller Resistenz gegen Antibiotika Peter Heisig Arzneimitteltherapie 12, 203-218 (1994) |
| 75 |
Mechanisms of Quinolone Resistance Bernd Wiedemann; Peter Heisig Infection 22 (Suppl. 2) S73-S79 (1994) |
| 76 |
Clinical significance and spread of fluoroquinolone resistant uropathogens in hospitalised urological patients Kurt Georg Naber; Florian Wagenlehner; Wolfgang Witte; Ingo Klare; Adolf Bauernfeind; Bernd Wiedemann; Peter Heisig Infection 22 (Suppl. 2) S122-S127 (1994) |
| 77 |
Quinolone-Resistance in Gram-Negative Bacteria Bernd Wiedemann; Peter Heisig Infectious Diseases in Clinical Practice 3 (Suppl. 3) S115-S126 (1994) |
| 78 |
Ciprofloxacin resistance in enterobacterial clinical isolates Peter Heisig; L. Tsouvelekis; A. Vatopoulos; Nicolas Legakis Journal of Antimicrobial Chemotherapy 33, 887-888 (1994) |
| 79 |
Adenylylsulfate reductase from the sulfate-reducing archaeon Archaeoglobus fulgidus: cloning and characterization of the genes and comparison of the enzyme with other iron-sulfur flavoproteins Norbert Speich; Christiane Dahl; Peter Heisig; Albrecht Klein; Friedrich Lottspeich; Karl O. Stetter; Hans-G. Trüper Microbiology 140, 1273-1284 (1994) |
1993 | |
| 80 |
Mutations in the gyrA gene of a highly fluoroquinolone-resistant clinical isolate of Escherichia coli Peter Heisig; Holger Schedletzky; Hildegard Falkenstein-Paul Antimicrobial Agents and Chemotherapy 37, 696-701 (1993) |
| 81 |
GyrA-Mutationen bei chinolonresistenten E. coli Peter Heisig; Holger Schedletzky; Hildegard Falkenstein-Paul Chemotherapie Journal 2, 18-23 (1993) |
| 82 |
High-level fluoroquinolone resistance in a Salmonella typhimurium isolate due to alterations in both gyrA and gyrB genes Peter Heisig Journal of Antimicrobial Chemotherapy 32, 367-377 (1993) |
| 83 |
Fluorierte Chinolon-Carbonsäuren: Wird der Fortschritt durch die Resistenzentwicklung aufgehoben? (Fluorinated quinolone carbonic acids. Are advances stopped by drug resistance development?) Bernd Wiedemann; Peter Heisig Pharmazie in Unserer Zeit 22, 286-295 (1993) |
1991 | |
| 84 |
Use of a broad-host-range gyrA plasmid for genetic characterization of fluoroquinolone-resistant Gram-negative bacteria Peter Heisig; Bernd Wiedemann Antimicrobial Agents and Chemotherapy 35, 2031-2036 (1991) |
| 85 |
Beurteilung der Resistenzentwicklung als Faktor für die Einschränkung therapeutischer Möglichkeiten Peter Heisig; Bernd Wiedemann Infection 19 (Suppl. 1) S47-S51 (1991) |
| 86 |
Genetische Grundlagen und Verbreitung von Fluorchinolonresistenz Peter Heisig; Bernd Wiedemann Fortschritte der Antimikrobiellen und Antineoplastischen Chemotherapie 10 (3) 223-232 (1991), Verlag: Paul-Ehrlich-Gesellschaft für Chemotherapie |
1989 | |
| 87 |
Comparison of the antimicrobial activity of cefuroxime with other oral antibiotics Bernd Wiedemann; Peter Heisig Journal of Chemotherapy Suppl. 4, 93-96 (1989) |
| 88 |
Bakterielle Resistenz gegen 4-Chinolone: Mechanismus und Bedeutung (Bacterial resistance to 4-quinolones: mechanisms and importance) Peter Heisig; Bernd Wiedemann Fortschritte der Antimikrobiellen und Antineoplastischen Chemotherapie 8 (1) 5-14 (1989), Verlag: Paul-Ehrlich-Gesellschaft für Chemotherapie |
1987 | |
| 89 |
Das mom-Gen des Bakteriophagen Mu Peter Heisig -/- Betreuer: T. A. Trautner; Bernd Wiedemann; Regine Kahmann Dissertation, Bonn (1987) |
1986 | |
| 90 |
The sequence and mom-transactivation function of the C gene of bacteriophage Mu Peter Heisig; Regine Kahmann Gene 43, 59-67 (1986) |
